会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • TREATMENT OF NON-PROLIFERATIVE CYSTIC DISEASE
    • 非增殖性疾病的治疗
    • WO2012074559A2
    • 2012-06-07
    • PCT/US2011001954
    • 2011-12-02
    • UNIV NEW YORKKLEINBERG DAVID L
    • KLEINBERG DAVID L
    • A61K39/395A61K38/31A61P35/00C12Q1/02G01N33/573
    • G01N33/5011A61K38/12A61K38/16A61K38/31G01N33/5088G01N33/57415G01N2800/365
    • The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.
    • 本发明一般涉及乳腺非增生性囊性疾病的治疗。 更具体地说,本发明一般涉及BRCA1突变体携带者乳腺非增殖性囊性疾病的治疗。 因此,本发明涉及抑制胰岛素样生长因子I(IGF-I)或胰岛素样生长因子I受体信号传导治疗非增殖性囊性疾病的化合物或试剂(包括生长抑素类似物)的用途和应用 的乳房 本发明还涉及这些化合物或药剂在BRCA1患者中用于治疗乳腺非增殖性囊性疾病的用途和应用。 本发明还涉及生长抑素类似物SOM230在治疗乳腺非增殖性囊性疾病中的用途,更具体地说,涉及使用生长抑素类似物SOM230来治疗BRCA1相关的非增殖性囊性疾病。
    • 2. 发明申请
    • METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF
    • 检测前列腺细胞的方法及其用途
    • WO2013019923A3
    • 2013-04-25
    • PCT/US2012049276
    • 2012-08-02
    • UNIV NEW YORKKLEINBERG DAVID LBARCELLOS-HOFF MARY HELEN
    • KLEINBERG DAVID LBARCELLOS-HOFF MARY HELEN
    • A61K38/30A61K38/18A61K48/00A61P35/00
    • A61K38/12A61K38/31G01N33/57415G01N2800/50G01N2800/52
    • Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients. Therapeutic methods are also encompassed herein, which include detection of PR/p63+ progenitor cells in a patient, wherein detection of increased frequency of PR/p63+ progenitor cells provides information on which basis a determination of therapeutic regimen or an assessment of an ongoing therapeutic regimen can be made.
    • 涉及乳房,子宫和卵巢的疾病和病症的诊断和治疗方法包括在本文中。 更具体地说,本文描述了用于早期检测乳腺癌,子宫癌和卵巢癌的祖细胞的诊断方法。 鉴定这些易患前体细胞(共表达孕激素受体(PR)和p63)的标志物提供了有助于早期检测PR / p63双阳性(PR / p63 +)祖细胞频率增加的工具和使用方法 细胞在无症状患者中的表达,从而早期发现此类患者的癌症风险增加以及评估,诊断分层和评估症状患者的治疗干预。 本文还包括治疗方法,其包括检测患者中的PR / p63 +祖细胞,其中PR / p63 +祖细胞频率增加的检测提供了关于治疗方案的确定或正在进行的治疗方案的评估的基础的信息 被制造。